Navigation Links
Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products
Date:5/12/2008

arly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

Contact Information:

Gary Spinell, Vice President

Investor Relations

972-471-6512

ir@mannatech.com

Corporate website: http://www.mannatech.com


'/>"/>
SOURCE Mannatech, Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Study validates Pittsburgh Compound-B in identifying Alzheimers disease brain toxins
2. NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures
3. Mannatech Launches Business in South Africa
4. Sports Illustrated Names Team Mannatech Athlete to Top 25 Tough List
5. Mannatech Goes Green and Supports Local Earth Day Celebrations
6. Mannatech to Begin Selling Nutritional Supplements in South Africa
7. Mannatech Names New VP of Regulatory Affairs, Quality Assurance
8. Mannatech to Open Centralized-Management Office in Switzerland
9. Mannatech Hosts Australasian Convention
10. Mannatech Hosts Japan National Convention
11. Mannatech Launches Phase One of New Sales and Training Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...ns of influenza activity 2-4 weeks in advance in t... // Though there are outbreaks of influenza any ti...e announced which would act as a caution to people...es like vaccination. In a prediction market, peopl...
..., also called magic mushrooms can effectively redu...OCD), according to a study// by University of Ariz...es like psilocybin, psilocin, or muscimol. The fir...approved) was outlawed in 1970, according to AP re...
...ntiretroviral treatment (HAART), people with HIV m...ncies and abnormalities. // In two different stud...n the Department of Public Health and Family Medic...cine, and colleagues examined the incidence of met...
...lood to the part of the brain affected is interrup...iously damaged or die, impairing local brain funct... of a stroke, new blood vessels begin to form, and...ns migrate long distances to the damaged area to a...
Other Medicine News:Health News:The Outbreak of Influenza is Now Predicted 2Health News:HIV Treatments Improve Health, but Nutritional Issues Remain 2Health News:HIV Treatments Improve Health, but Nutritional Issues Remain 3Health News:Cellular Cues Identified for Stroke Recovery 2
(Date:9/3/2008)...s Phase 3 Plans with FDA, PRINCETON, N.J., Sept. ...ced today that it successfully completed two key c... new, innovative low-dose, once-weekly,contracept...rnal product,code AG-200-15. The Phase 2b safety a...point of ovulation suppression, cycle control and ...
(Date:9/3/2008)...trong Evidence Pycnogenol(R) Lowers Joint, Pain, S...lowing Cessation of th... According to the Center for,Disease Control (CDC)...s,is on the rise. A new study published in the Au...nogenol(R), bark extract from the French maritime ...
(Date:9/3/2008)...wswire-FirstCall/ -- A sub-analysis of,the TRITON-...prasugrel,compared with clopidogrel significantly ... (7.4 percent vs. 9.7 percent, p<0.0001), regardle...of an artery-opening,procedure known as percutaneo...d spontaneously during the longer-term maintenance...
(Date:9/2/2008)...-FirstCall/ --, - This Analysis Showed That Multa... 34% in Patients With Atrial Fibrillation or Atria...otic Therapy, The results of a post-hoc analysis ...oday at the clinical trial update session of the E...nich, Germany. Previous results,from the landmark ...
Breaking Medicine Technology:Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sinexus Welcomes New CEO and Completes Series B 21149 1Sinexus Welcomes New CEO and Completes Series B 21149 2Sinexus Welcomes New CEO and Completes Series B 21149 3Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 1Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 2Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 3Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 1Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 2Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 1Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 2Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 4
...zed phase II/III clinical trial,anticipated later ...tCall/ -- Cell,Therapeutics, Inc. (CTI) announced ...nstrate that treatment with pixantrone (BBR,2778) ...ty, while,doxorubicin and mitoxantrone induced sig...cardiac side effects of equiactive doses,of pixant...
...WIRE)--Jun 26, 2007 - Sirtris,Pharmaceuticals, Inc...sed on discovering and developing small molecule d...hat activation of SIRT1, a,member of the sirtuin f...rodegenerative diseases such as Alzheimer,s Diseas...ls. These findings,appear in an article published ...
Other Medicine Technology:Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 2Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 3
High sensitive, specific one step immunochromatographic assay for human infectious disease
Span Diagnostics Limited
Malaria (P. fal.) Ag Rapid Test
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria).
Medicine Products: